Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Boehringer starts plant, expands China R&D

by Jean-François Tremblay
May 22, 2017 | A version of this story appeared in Volume 95, Issue 21

Boehringer Ingelheim has started up a $78 million biopharmaceutical plant at the Zhangjiang Hi-Tech Park in Shanghai. The facility, the company claims, is the only biopharmaceutical plant started up in China by a major international producer. Boehringer plans to use the plant to supply monoclonal antibodies and recombinant proteins to its customers in China. Separately, Boehringer announced that it will fund early drug discovery projects at Peking University. Several academic investigators will work closely with the German firm, Boehringer says.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.